Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

IN8bio, Inc. – Common Stock Q2 EPS $(0.38) Up From $(1.00) YoY

IN8bio, Inc. – Common Stock (NASDAQ:INAB) reported quarterly losses of $(0.38) per share. This is a 62 percent increase over losses of $(1.00) per share from the same period last year.
byMichael Horton
August 12, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

IN8bio, Inc. – Common Stock (NASDAQ:INAB) reported quarterly losses of $(0.38) per share. This is a 62 percent increase over losses of $(1.00) per share from the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Tiziana Announced Collaboration Agreement with FHI Clinical to Conduct a Phase 2 Clinical Trial for Treating Hospitalized Severe COVID-19 Patients with Intranasal Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody

By Charles Gross
Today, 4:46 AM
Tiziana Life Sciences plc (NASDAQ: TLSA) announces that it has signed an agreement with FHI Clinical, a global clinical contract research organization (CRO), to conduct a Phase 2 Proof-of-concept study in Brazil to evaluate the safety, tolerability and efficacy of intranasal Foralumab in hospitalized patients with severe coron

TLSA